Literature DB >> 6903190

Partial properdin deficiency.

C A Davis, J Forristal.   

Abstract

The action of properdin in supporting complement consumption has been investigated in the serum from two individuals with partial properdin deficiency. Our studies are in agreement with those in which serum were artificially depleted of properdin in showing that serum deficient in properdin results in less C3 consumption in the presence of activators of both the alternative and classical complement pathways. Properdin deficiency did not lessen C3 consumption by C3NeF or CoF, confirming that properdin is not necessary for the action of these substances. Our findings indicate that partial properdin deficiency is innocuous but that complete absence of properdin may severely limit one's ability amplify complement activation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6903190

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  4 in total

1.  Carrier detection in families with properdin deficiency by microsatellite haplotyping.

Authors:  K Kölble; A J Cant; A C Fay; K Whaley; M Schlesinger; K B Reid
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

2.  Properdin deficiency in a family with fulminant meningococcal infections.

Authors:  A G Sjöholm; J H Braconier; C Söderström
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

3.  Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.

Authors:  Bert Gold; Joanna E Merriam; Jana Zernant; Lisa S Hancox; Andrew J Taiber; Karen Gehrs; Kevin Cramer; Julia Neel; Julie Bergeron; Gaetano R Barile; R Theodore Smith; Gregory S Hageman; Michael Dean; Rando Allikmets
Journal:  Nat Genet       Date:  2006-03-05       Impact factor: 38.330

4.  Granulocyte phagocytosis of Streptococcus pneumoniae in properdin-deficient serum.

Authors:  J H Braconier; H Odeberg; A G Sjöholm
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.